Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 4,175 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control comparison Clear all

Conditions: Influenza
Interventions: Flublok Quadrivalent, Inactivated Influenza Vaccine (IIV4); Biological
Lead sponsor: Protein Sciences Corporation; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 1,350 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 10
States / cities: Sacramento, California • Coral Gables, Florida • Savannah, Georgia + 7 more

Conditions: Wound Debridement
Interventions: HemCon Dressings and HemCon ChitoGauze; chitosan-based., Gauze and saline dressings.; Device
Lead sponsor: HemCon Medical Technologies, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Patients Receiving Physical Therapy
Interventions: Strength education video, standard PT care; Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Substance-Related Disorders, Alcohol-Related Disorders
Interventions: The Women's Recovery Group, Group Drug Counseling; Behavioral
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 2
States / cities: Belmont, Massachusetts • Fall River, Massachusetts

Conditions: Major Depressive Disorder
Interventions: Ketamine, Psychotherapy; Drug · Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 90 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Communication Research
Interventions: Communication type; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: Not listed
Enrollment: 11,120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypertension, Diabetes Mellitus, Type 2
Interventions: telmisartan combined with hydrochlorothiazide (80/12.5 mg), valsartan combined with hydrochlorothiazide (160/12.5mg); Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 30 Years and older
Enrollment: 840 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 60
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 47 more

Conditions: D3 Dopamine Receptor, Cocaine-dependent, Healthy Volunteer
Interventions: [18F]FTP PET/CT; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Acute Myeloid Leukemia
Interventions: Lintuzumab (SGN-33), Low dose cytarabine, Placebo; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 60 Years and older
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 20
States / cities: Mobile, Alabama • Beverly Hills, California • Glendale, California + 16 more

Conditions: Atopic Dermatitis
Interventions: Oregano extract cream, Hydrocortisone; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 2 Years to 17 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Somerset, New Jersey

Conditions: Coronary Artery Disease, Postoperative Pain, Respiratory Failure
Interventions: Rectus sheath block with bupivacaine; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 85 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Hepatic Impairment
Interventions: MEK162; Drug
Lead sponsor: Array Biopharma, now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 5
States / cities: Lakewood, Colorado • Miami, Florida • Orlando, Florida + 2 more

Conditions: Type 2 Diabetes, Obesity
Interventions: Portion-controlled diet, Usual Diet; Other · Dietary Supplement
Lead sponsor: Nutrisystem, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Smoking ( Cigarette)
Interventions: Nicotine 0.05 mg/pulse and 0.1 mg/pulse, Saline Placebo (0.5mL injection), sucralose, Sugar syrup (Placebo); Drug · Dietary Supplement
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 59 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Rheumatoid Arthritis
Interventions: fostamatinib, placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 67
States / cities: Anniston, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 64 more

Conditions: Allergic Conjunctivitis
Interventions: Ketotifen 4.0% Patch, Placebo, Olopatadine 0.2%, Artificial tears; Drug
Lead sponsor: Senju USA, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Chronic Kidney Disease
Interventions: Diet counseling, Phosphorus binder; Other · Drug
Lead sponsor: Salem Veterans Affairs Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Salem, Virginia

Conditions: Chronic Pain
Interventions: AtEase, Chronic Pain Education; Behavioral
Lead sponsor: Pro-Change Behavior Systems; Other
Eligibility: 18 Years and older
Enrollment: 268 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: West Haven, Connecticut • South Kingstown, Rhode Island

Conditions: Covid19
Interventions: IFN beta-1a, Dexamethasone; Drug
Lead sponsor: Faron Pharmaceuticals Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Aurora, Colorado • Boston, Massachusetts • Newton, Massachusetts + 1 more

Conditions: Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
Interventions: Canakinumab 150 mg, Placebo to Canakinumab; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 11
States / cities: Los Angeles, California • Santa Ana, California • Spring Valley, California + 7 more

Conditions: Congenital Heart Disease
Interventions: 3D model of heart; Other
Lead sponsor: Columbia University; Other
Eligibility: Not listed
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 6
States / cities: Palo Alto, California • Gainesville, Florida • Atlanta, Georgia + 2 more

Conditions: Critically Ill
Interventions: Nocturnal coverage; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 1,609 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: QVA149, Umeclidinium/vilanterol, Placebo (umeclidinium/vilanterol), Placebo (QVA149); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 357 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 58
States / cities: Andalusia, Alabama • Anniston, Alabama • Jasper, Alabama + 52 more

Conditions: Gastrointestinal Stromal Tumors
Interventions: Masitinib, Imatinib; Drug
Lead sponsor: AB Science; Industry
Eligibility: 18 Years and older
Enrollment: 335 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 7
States / cities: Orlando, Florida • Atlanta, Georgia • Detroit, Michigan + 4 more

Search by objective public record fields.

Safety and Immunogenicity of Flublok Quadrivalent vs IIV4 in Adults 18-49 Years of Age

Chitosan Dressings to Facilitate Safe Effective Debridement of Chronic Wounds & Minimize Wound Bacterial Re-colonization

Does a Video-based Education Tool Related to Strengthening Result in Different Functional Outcomes Compared to Traditional Physical Therapy Education for Patients?

Women's Recovery Group (WRG) Study - A Randomized Controlled Stage II Trial

Ketamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of Depression

Project Resurgence Communication Trial

SMOOTH - Blood Pressure Control in Diabetic/Obese Patients

Evaluation of D3 Receptor Occupancy Using FLUORTRIOPRIDE ([18F]FTP) PET/CT

A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML

Oregano Ointment vs. Standard Treatment for Pediatric Atopic Dermatitis

Pectointercostal Fascial Plane Block (PIFB) Alone Versus PIFB With Rectus Sheath Block (RSB) in Cardiac Surgery

MEK162 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function

Blood Glucose Stability and Variability on Two Diets

Impact of Sweeteners on the Addictive Threshold of Nicotine

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Evaluation of the Safety and Efficacy of Ketotifen 4.0% Patch as Compared to Placebo Patch, Olopatadine 0.2% Ophthalmic Solution, and Artificial Tears in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis

Study Comparing Effects of Lanthanum Carbonate Versus Calcium Acetate Versus Dietary Phosphorus Restriction

Evidence-based Pain Intervention for Veterans: AtEase for Chronic Pain

Human Intravenous Interferon Beta-Ia Safety and Preliminary Efficacy in Hospitalized Subjects With COVID-19

To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies

Implementing Models for Mechanical Circulatory Support Presurgical Assessment in Congenital Heart Disease Treatment

24 Hour Intensivist Coverage in the Medical Intensive Care Unit

Efficacy and Safety Study of QVA149 in COPD Patients

Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)